AI Eye Podcast 695: Stocks discussed: (ASX: BRN) (TSX: DTOL)


Vancouver, Kelowna, Delta, BC – May 16, 2022 ( Newswire), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

AI Eye Podcast 695: Stocks discussed: (ASX: BRN) (TSX: DTOL)


Hear the AI Eye on Spotify

Today’s Column – The AI Eye – Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (ASX:BRN) (TSX:DTOL)

BrainChip Holdings Ltd. (ASX:BRN) and Edge Impulse, a development platform for machine learning (ML) on edge devices, are partnering to deliver next-generation platforms to customers looking to develop products utilizing the companies’ machine learning capabilities. Jerome Nadel, BrainChip’s CMO, said:

“Partnering with Edge Impulse creates a unique market solution that brings their powerful and easy to use AI/ML application design platform unparalleled performance with BrainChip’s silicon proven on-chip learning and ultra-low power IP. We continue to look for partnerships that will advance opportunities to enable a wide array of edge AI capabilities, such as continuous learning and real-time inference. Edge Impulse is a perfect addition to our ecosystem of providers enabling next-generation technology to markets around the world.”

Global learning technology company D2L Inc. (TSX:DTOL) has announced an expansion in its use of intelligent technology, including artificial intelligence, smart workflow design, and automation, to “help educators personalize learning.” John Baker, President and CEO of D2L, said:

“For more than a decade, D2L has been at the forefront of building intelligent tools within our products to make it easier to build engaging experiences and get the right feedback to learners when they need it the most. Personalizing learning is not easy, and our goal with intelligent tools is to help instructors save time, so they can focus on what really matters: improving outcomes for their learners.”

Global AI in Pharma to Reach $7.14B by 2029

A report published by Polaris Market Research finds that the global AI in Pharmaceutical market is projected to grow from $859.1 million USD in 2021 to $7.14 billion in 2029, registering a compound annual growth rate (CAGR) fo 31.2 percent in the forecast period 2022-29. The following excerpt from the report’s description outlines the ways in which AI is being leveraged in the market:

Drug discovery, smart manufacturing, automated control processes systems, the prediction of new treatments, and the production of novel peptides from natural foods raise awareness for the use of AI in pharma.

Furthermore, pharma companies present across the global market are using advanced machine learning algorithms and AI-powered tools to speed up the drug discovery process. These technologies are designed to detect complex patterns in vast datasets and may thus solve problems related to complex biological networks.

Sam Mowers,

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on visit here

About – News that Inspires Big Investing Ideas publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

The podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher,, iHeartRadio, Google Podcasts and most audio platforms available.

Visit the Podcast page at

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the newswire Global investors must adhere to regulations of each country. Please read privacy policy:

The AI Eye – Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of

Follow us on Twitter

Follow us on Facebook

Follow us on YouTube


800 665 0411

Buy a technology guest post on

Biotech Stock News: Nova Mentis (CSE: NOVA) Welcomes Autism Behaviour Analyst to its Science Team

Previous article

Here’s Why I’m Bullish on Gold Miners

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News